Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donna Smith

Auburn, WA Medical Doctor

NPI 1225389935 CMS profile 55161

122 3Rd St Ne, Auburn, WA 98002

Open in the dashboard

General payments

$907

24 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donna Smith of Auburn, WA is reported in the CMS Open Payments database as having received $907 across 24 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16 1
2024 General $50 2
2023 General $55 2
2022 General $650 12
2021 General $81 4
2019 General $55 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donna Smith
  • Washington median
  • Middle half of Washington
  • National median

In program year 2025, general payments to Donna Smith were reported at $16. Among 15,799 Washington profiles paid that year, the median was $133 and the middle half received between $42 and $442.

Show as a table
Year Donna Smith Washington median Middle half National median
2019 $55 $126 $38–$506 $163
2020 $0 $90 $30–$291 $114
2021 $81 $107 $29–$344 $132
2022 $650 $124 $38–$398 $149
2023 $55 $129 $40–$423 $160
2024 $50 $133 $44–$454 $164
2025 $16 $133 $42–$442 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $393 5 payments
  2. Smith+Nephew, Inc. $134 4 payments
  3. Medartis Inc. $64 1 payment
  4. Zimvie Inc. $52 2 payments
  5. Stryker Corporation $50 1 payment
  6. AxoGen $43 2 payments
  7. Abbott Laboratories $34 1 payment
  8. Endo USA, Inc. $33 2 payments
  9. Bard Access Systems, Inc. $25 1 payment
  10. Integra LifeSciences Corporation $21 1 payment
  11. Other $59 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $725 22 payments
  2. Travel and Lodging $182 2 payments
Products named General payments · program years 2019–2025
  1. ROSA $182 2 payments
  2. Accelero-None $167 2 payments
  3. APTUS $64 1 payment
  4. EVOS $54 1 payment
  5. OMEGA $50 1 payment
  6. CMI $50 1 payment
  7. XIAFLEX $47 3 payments
  8. Avance Nerve Graft $43 2 payments
  9. EVOS MINI $34 1 payment
  10. PROCLAIM $34 1 payment
  11. Other $299 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

68

Median for Hand Surgery: 118

Drug cost

$357

Median for Hand Surgery: $615

Branded share of claims

33.8%

Median for Hand Surgery: 34.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 32 $144
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $138
Tramadol Hcl Generic 13 $76

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,399 Part D prescribers listed as Hand Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$70,877

Of which drugs: $698

Medicare patients

206

Average age 75

Services billed

1,209

122 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Ischemic heart disease 25%
Depression 23%
Osteoporosis 23%
Diabetes 21%
Chronic kidney disease 20%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 90 487 $354

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIAFLEX
  • Endo USA, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

24 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record